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ABSTRACT
Aim: Aims of this study were to evaluate the efficacy of a cow’s milk protein (CMP)
elimination diet on induction and maintenance of remission and to define association with
atopy in children with ulcerative colitis (UC).
Methods: Twenty-nine consecutive patients (mean age: 11.2 years; range: 4.6–17 years;
F/M: 15/14) with newly diagnosed UC were randomized either to receive a CMP
elimination diet (n = 14) or to continue a free diet (n = 15) associated with concomitant
steroid induction and mesalazine maintenance treatment. Children were prospectively
evaluated at four time points: within 1 month, 6 months and 1 year after diagnosis or at
the time of relapse.
Results: Twenty-five of the 29 enrolled patients responded to the UC induction therapy
with a complete remission (86.2%), 13 belonging to CMP elimination diet group and 12 to
free diet group (p = 0.59). Overall, our data showed that 7 of 13 (53.8%) patients treated
with CMP elimination diet and 8 of 15 (53.3%) patients on free diet and UC therapy
relapsed within 1 year of follow-up (p = 1).
Conclusions: In conclusion, data of this paediatric, randomized trial suggest that CMP
elimination has no role in the management of UC in non-sensitized children.
INTRODUCTION
Food sensitivity/intolerance has been suggested to play a
role in the aetiology of IBD, and the culpable foods vary on
an individual basis. The foods excluded have been predom-
inantly cereals, dairy products, yeast and certain types of fat
(1). In particular, children with IBD often avoid dairy
products more than they would need to, based on the
prevalence of lactose malabsorption and/or allergy to milk
proteins because of arbitrary advice from physicians. In a
study by Jowett et al., 68% of UC adult patients believed
that diet influenced their disease and modified their diet
accordingly. The most common behaviour resulted the
avoidance of milk and dairy products; this dietary change
resulted in reduced calcium intakes but had no apparent
effect on the rate of relapse (2). On the other hand,
malnutrition is very common in children with IBD (3). At
the time of diagnosis, up to 85% of paediatric patients with
CD and 65% of patients with UC have weight loss (4).
Unnecessary dietary exclusions are a concern if initiated
without appropriate nutritional or medical supervision,
given the importance of adequate calcium and vitamin D
intakes in the prevention of osteoporosis in IBD (5). The
origins of malnutrition in IBD are multifactorial, but dietary
restrictions (due to intolerance of diet or therapeutic
fasting) are considered to be relevant (6). Without further
evidences, and considering the nutritional issues, it remains
unclear whether dietary manipulation will continue to have
a role solely in symptom control, or whether complete
remission may be possible using these methods in combi-
nation with pharmacological agents.
The purposes of this study were to evaluate the efficacy of
a cow’s milk protein (CMP) elimination diet on induction
and maintenance of remission and to define the association
with atopy in children with ulcerative colitis (UC).
METHODS
This was a prospective, single-centre, randomized, con-
trolled, 1-year study of children with newly diagnosed UC
consecutively enrolled at the Department of Translational
Medical Sciences, Section of Pediatrics, University of
Naples ‘Federico II’, Italy. Twenty-nine consecutive
patients (mean age: 11.2 years; range: 4.6–17 years; F/M:
Key notes
 Allergy to milk protein has been reported to play a
possible role in the etiopathogenesis of UC.
 Unnecessary dietary exclusions are a concern if initiated
without appropriate nutritional or medical supervision.
 Data of this paediatric, randomized trial suggest that
cow’s milk protein elimination diet does not modify the
time of induction and the risk of relapse.
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15/14) with newly diagnosed UC, based on accepted
historical, endoscopic, histological and/or radiological cri-
teria (7), were randomized either to receive a CMP
elimination diet (n = 14) or to continue a free diet (n = 15).
All patients with a Pediatric Ulcerative Colitis Activity
Index (PUCAI) score 35 received concomitant steroid
induction treatment (oral methylprednisolon: 1 mg/kg/day,
maximum 40 mg/day per 4 weeks) and oral mesalazine
induction and mesalazine maintenance treatment (50 mg/
kg/day), while subjects with a PUCAI score <35 received
exclusively oral mesalazine induction and mesalazine
maintenance treatment (50 mg/kg/day). The paediatric
gastroenterologists (AS; EM) made all decisions regarding
induction therapeutic intervention being unaware of diet
group allocation. A detailed list of food containing milk
proteins was given to each patient to avoid them during the
elimination diet period. During the study period, parents
and/or patients were asked to record in a daily diary only
the amount and type of not allowed food. At the end of the
study, these diaries were analysed to evaluate adherence to
the diet and the quantity of milk consumed. The parents
were able to contact one of the investigators (MM)
whenever necessary, and frequent telephone contacts
helped to ensure adherence to the diet. All children
received supplemental elemental calcium 1000 mg/day
and vitamin D3 0.25 mcg/day for 1 year. Exclusion criteria
were children who had received therapy-inducing remis-
sion of UC and/or children who required surgery for
complications related to UC.
Assignment to CMP elimination diet or free diet was
determined according to a computer-generated randomiza-
tion scheme. Excellent compliance was defined as no
violation of the protocol with respect to the intake of the
diet.
After 4 weeks, patients who were in remission began
tapering off corticosteroids on a weekly basis (25%/week)
on the basis of the PUCAI score. Upon induction of
remission patients continued to receive concomitant ther-
apy (CMP elimination diet group: mesalazine and CMP
elimination diet; free diet group: mesalazine and free diet)
for 1 year or until relapse.
Additional information collected at the first visit included
demographic data, family history and symptom onset. At
diagnosis, physical examination was performed by a paedi-
atrician and included an abdominal examination and
evaluation of extraintestinal manifestations of UC. Age-
and gender-specific z-scores (standard deviation scores) for
height and weight were calculated using National Center
for Health Statistics 2000 Center for Disease Control data.
The PUCAI and physician global assessment (PGA) were
used to measure disease activity (8). The extension of
disease involvement was evaluated using the Paris Classi-
fication (9). Clinical remission was defined on the basis of
PUCAI < 10, while clinical response to the induction
treatment was identified as a PUCAI score a change of at
least 20 points from baseline. Clinical relapse was defined
as the occurrence or worsening of symptoms accompanied
by an increase of PUCAI >10 points, sufficient to require
rescue treatment with corticosteroids, azathioprine/immu-
nosuppressive agents, or surgery. When a relapse occurred,
the study protocol was stopped and the patient was treated
according to the physician’s preference. Laboratory studies
including complete blood count, albumin, ESR, CRP,
calcium and phosphorus were performed at first visit.
Children were prospectively evaluated at four time
points: at diagnosis, within 1 month, 6 months and 1 year
after diagnosis or at the time of relapse. At diagnosis and at
12 months or at the time of relapse all patients were
assessed endoscopically and histologically. Colonoscopic
grade of inflammation was determined by use of Matts’
colonoscopy grading score (10). Colonoscopy report system
required segmental descriptions (rectum, sigmoid, descend-
ing, transverse and ascending colon, and caecum). From the
information provided on the colonoscopy report, for each
segment of the colon was designated a score, and a mean
score for that colonoscopy was derived. All histologic
specimens were reviewed under code by a single pathologist
experienced in analysing paediatric intestinal biopsies,
blinded to the patients’ clinical details, who scored biopsies
according to the Matts’ histologic criteria (10).
At baseline, a detailed questionnaire was completed for
each subject and control, including details of family,
personal history of atopic disease and the presence of
allergic symptoms. Family and personal history of atopic
disease as well as the presence of allergic symptoms in
children were established through the use of the validated
ISAAC questionnaire (11). Skin prick tests (SPT) were
performed according to a standard technique for common
inhalational (Dermatophagoides pteronyssinus and farinae,
graminacea, parietaria and cat dander) and dietary aller-
gens (whole milk, alpha-lactoalbumin, beta-lactoglobulin,
casein, albumin, egg yolk and fish) (Lofarma, Milano,
Italy). The tests were carried out on the volar side of the
forearm with disposable prick lancettes by one physician
who was not aware of the subject’s clinical history (MM).
Histamine chloride at 10-mg/mL and glycerosaline solution
were used as positive and negative controls. After 15 min,
weal diameters >3 mm, compared with positive and nega-
tive controls were considered positive. Specific IgE levels
were considered positive if >0.70 kU/L, as the reported
reference ranges for the commercial test used in our
laboratory (Unicap-specific IgE allergen immuno cap,
manufactured by Pharmacia). Subjects with specific IgE
and/or prick tests positive for at least one allergen and a
personal history of atopy (such as recurrent symptoms of
rhinitis, dermatitis, bronchospasms) were considered atopic
children.
Statistical analysis
Data were analysed for all patients who had completed at
least two visits. Means and medians were calculated for
dimensional variables after controlling for normality of
distribution. Statistical analysis was carried out using SPSS
statistical software package for Windows (13.0; SPSS Inc.,
Chicago, IL, USA). The Student’s t-test and Mann–Whitney
U-test for normally distributed variables and the chi-
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squared and Fisher exact tests for categorical variables were
used where appropriate. Survival analysis was used to
analyse the data set with respect to relapse. The Kaplan–
Meier method was used to estimate the survivor function,
and comparison of cumulative relapse rates between treat-
ment groups was tested by the log-rank test. The study was
approved by the Institutional Review Board of the Univer-
sity of Naples ‘Federico II’. Written, informed consent was
obtained from participants’ parents, and assent was
obtained for all patients older than 10 years of age.
RESULTS
Thirty-two patients with newly diagnosed UC were
screened. Three subjects were excluded, because the par-
ents of two refused consent and one had received previous
steroid therapy for the presence of concomitant disease
(asthma). Twenty-nine children were eligible and partici-
pated to this study and were randomly assigned to receive a
CMP elimination diet or to continue a free diet associated
with concomitant steroid and/or mesalazine induction and
mesalazine maintenance treatment. Demographic data for
the study groups are listed in Table 1.
The mean PUCAI performed at diagnosis by the paedi-
atric gastroenterologist of each patients did not show
significant differences between CMP elimination diet and
free diet patients (p = 0.5; OR 1.25; 95% CI 0.9–1.7)
(Table 1).
On the basis of the PGA, the severity of the disease was
mild in 14.3% of CMP elimination diet patients vs. 33.3% of
free diet patients, moderate in 42.9% of CMP elimination
diet subjects vs. 53.3% of free diet subjects and severe in
42.9% of CMP elimination diet children vs. 13.3% of free
diet group (p = 0.3).
Twenty-five of the 29 enrolled patients responded to the
IBD induction therapy with a complete remission (86.2%),
12 belonging to free diet group and 13 to CMP elimination
diet group (p = 0.59). Three patients had a partial response,
whereas 1 patient did not respond to induction therapy.
Overall, our data showed that 7 of 13 (53.8%) patients
treated with CMP elimination diet and 8 of 15 (53.3%)
patients on free diet and IBD therapy relapsed within 1 year
of follow-up (p = 1; OR = 0.8; CI = 0.2–3.7). Among them,
26.6% (4/15) and 38.4% (5/13) relapsed within the first
6 months (p = 0.45). Life-table analysis of the relapses in
the 2 groups is showed in Figure 1.
Among the CMP elimination diet group, 6 (42.8%)
patients were treated with steroids and mesalazine, while
8 (57.2%) patients received mesalazine alone. Ten (66.6%)
patients of the free diet group were treated with steroid
Table 1 Baseline characteristics and at 1 year follow-up or at time of relapse in 29 children with newly diagnosed UC
Characteristics
Cow’s milk protein (CMP)
elimination diet group Free diet group
p
CMP elimination diet group Free diet group
p
T0 T12 or at Time of Relapse
Sex (n, %)
Male 9 (64.3%) 5 (33.3%) 0.1
Female 5 (35.7%) 10 (66.7%)
Median Age (months; range) 134.5 (57–196) 138 (55–204) 0.8
Male 145 (57–196) 157 (81–172) 0.5
Female 124 (112–173) 133 (55–204) 0.8
Mean Z-Score (range) 0.18 (3 to 2) 0.3 (1.5 to 2) 0.4 0.23 (0.5 to 2.47) 0.6 (1.1 to 2.2) 0.3
Duration of breast feeding (days, median, range) 97.5 (1–745) 90 (1–262) 0.3
Introduction of cow’s milk (days, median, range) 106 (1–185) 100 (1–170) 0.4
PUCAI (median, range) 36.2 (15–45) 31 (15–55) 0.5 24 (0–85) 17.5 (0–65) 0.6
Paris classification (n, %)
Negative (E0) 0.2 3 (21.4) 2 (13.3) 0.2
Proctosigmoiditis (E1) 4 (28.5) 3 (20) 2 (14.3) 2 (13.3)
Left-sided colitis (E2) 1 (7.1) 2 (13.3) 2 (14.3) 4 (26.6)
Extensive colitis (E3) 1 (7.1) 5 (33.3) 2 (14.3) 3 (20)
Pancolitis (E4) 8 (57.1) 5 (33.3) 5 (35.7) 4 (26.6)
Endoscopic Matt score (mean, range) 1.7 2.2 0.7 2.2 2.5 0.5
Histological Matt score 2.6 2.6 0.8 1.8 2.1 0.4
Steroid therapy 6 (80%) 10 (50%) 0.3
Time to weaning
Steroids (days, median, range) 55 (30–60) 60 (30–120) 0.7
Total amount of Steroid
Induction Therapy (mean mg/kg) 0.78 0.83 0.3
Hemoglobin (median, range) 11.7 (5.5–14.1) 11.7 (7–14.3) 0.9 11.5 (7–14.2) 12.1 (9.4–13.7) 0.6
CRP (median, range) 0.3 (0.2–9.1) 0.7 (0.2–19.1) 0.1 0.6 (0.3–86.7) 0.3 (0.3–33.5) 0.6
ESR (median, range) 6.5 (3–25) 13 (3–46) 0.1 12 (1–60) 4 (2–20) 0.3
Calprotectin (median, range) 434.5 (60–500) 369 (15–500) 0.5 144.5 (15–500) 416.5 (53–500) 0.3
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therapy and 5 (33.4%) with mesalazine alone. Overall, the
number of relapses was significantly higher in patients
treated with steroids and mesalazine versus patients receiv-
ing mesalazine alone (12 vs. 3; p = 0.009). No other
significant differences were observed among the other
therapeutic subgroups.
At time of enrolment, endoscopic and histological scores
were not statistically different comparing the CMP elimi-
nation diet and free diet groups (p = 0.7 and p = 0.8)
(Table 1). At baseline, laboratory parameters including
haemoglobin, erythrocyte sedimentation rate and C-reac-
tive protein were not significantly different between the two
groups and were not predictive of response and/or relapse
(Table 1). Hypereosinophilia was present in 2 patients
(6.9%), one from the CMP elimination diet group and 1
from free diet group. At 12 months or at time of relapse,
endoscopic and histological scores were not significantly
different among the CMP elimination diet group and the
free diet group. All patients were compliant to the dietary
restrictions.
No side effects or significant changes from baseline
values in any of the laboratory parameters examined
attributable to CMP elimination diet was registered.
All 29 patients completed the questionnaire. Family
history of atopy was present in 4 patients on CMP
elimination diet (28.6%) and in five patients on free diet
(33.3%) (p = 1). Based on the criteria listed under the
Methods section, the prevalence of atopy in our study
population was 27.5%. Four patients on CMP elimination
diet (28.6%) and in five patients on free diet (33.3%) also
satisfied the diagnostic criteria for atopy (p = 1). Positive
laboratory results consistent with atopy for these patients
are summarized in Table 2. None of the patients had
symptoms of cow’s milk allergy. On the basis of PUCAI,
remission was achieved in four atopic patients (100%)
treated with elimination diet and IBD therapy and in four
atopic patients (80%) treated with free diet and IBD therapy
(p = 1). One patient treated with free diet and IBD therapy
had just a partial response. Two of four (50%) atopic
patients treated with CMP elimination diet and IBD therapy
and one of five (20%) atopic patients on free diet relapsed
within 1 year of follow-up (p = 0.5).
DISCUSSION
In this study, we did not demonstrate a significant efficacy
of CMP elimination diet in the induction and maintenance
of remission in paediatric active UC. Patients receiving
CMP elimination diet and concomitant conventional ther-
apy did not have a significantly higher rate of remission
compared to children on free diet with not significantly
lower incidence of relapse within 1 year of follow-up.
The aetiology of IBD is considered multifactorial.
Genetic, infective and environmental theories exist, as well
as those centred around host immunity, intraluminal gut
flora, food allergies and hypersensitivity (12). Diet may
influence gut inflammation through several biologically
plausible mechanisms, including antigen presentation,
change in prostaglandin balance, and alteration of the
microflora (13). The belief that dairy products can exacer-
bate the disease and that patients restrict their consumption
has already been documented (14). From a historical
perspective, the concept of ‘milk allergy’ was introduced
in the early part of this century when it was believed that
foods and eating habits were involved in the pathogenesis of
IBD (15,16). The concept of ‘milk allergy’ as initially
proposed was not based on objective immunologic testing
and gradually gave way to theories involving malabsorption
of and ‘intolerance’ to lactose in the 1960s (17) and, more
recently, intolerance to other components of dairy products
(18). Allergy to milk proteins still remains a possible
cause of ‘dairy sensitivity’ or milk intolerance in a small
percentage of IBD patients (19). Even if, so far, the only
Figure 1 Kaplan–Meier estimates of relapse during treatment on cow’s milk
protein elimination diet or on free diet (log-rank test p = 0.87).
Table 2 Clinical and laboratory results in UC atopic children who satisfy criteria for
atopy
Cow’s milk protein elimination
diet group n (%)
Free diet
group n (%)
Family history of atopy 4 (28.6) 7 (46.6)
Associated symptoms 3 (21.4) 2 (13.3)
RAST 1 (7.1) 4 (26.6)
b Lactoglobulin 1 (7.1) 3 (20)
Dermatophagoides
pteronyssinus
1 (7.1) 2 (13.3)
Grass pollens 1 (7.1) 0
Cat dander 1 (7.1) 0
Parietaria 0 1 (6.6)




Parietaria 1 (7.1) 3 (20)
Grass pollens 2 (14.3) 1 (6.6)
Egg white 1 (7.1) 1 (6.6)
Cat dander 0 0
Casein 0 0
b Lactoglobulin 0 1 (6.6)
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recognized evidence is that the lack of breast feeding and an
increased prevalence of cow milk sensitivity may be risk
factors for the later development of IBD, clinicians still
focus on the foods that patients associate with their
symptoms and therefore avoid (20,21). However, several
reports have demonstrated that inadequate caloric intake is
the primary cause of growth retardation in IBD (22,23). All
clinicians should be aware that iatrogenic dietary restric-
tions, which are often imposed without a sound scientific or
clinical basis, further reduce the amount of calories
provided, contributing to the malnutrition and various
micronutrient deficiencies in paediatric IBD patients (24).
Analysing the different therapeutic subgroups (steroids
and mesalazine vs. mesalazine alone) within 1 year of
follow-up, we found a higher incidence of relapses in
patients under steroid therapy of both CMP and free diet
groups compared with patients treated with mesalazine
alone. This finding clearly highlights that neither steroids
nor CMP elimination diet were able to modify the natural
history of the disease. Patients eligible for steroid treatment,
and therefore with the worst onset of disease, continue to
act with the same severe phenotype despite a more
aggressive therapy.
The prevalence of atopy in our study population was
27.5%. Our results showed no difference in the prevalence of
atopy among UC children treated with elimination diet and
those on free diet. Nevertheless, due to the small number of
our patients, we cannot draw any conclusion in respect of the
association between atopy and UC. Several studies tried to
investigate the attractive hypothesis that IBD may be an
allergic response to food (21,25) especially in individuals
susceptible to various allergens. In particular, UC with Th2
cytokines pattern response has always been thought to be
somehow related to allergic diseases.Most studies confirmed
the observation that atopic features are more frequent in
patients with IBD than in the general population (26,27).
Only one study byTroncone et al. (28) showed that therewas
no correlation between atopy and IBD.
Our study has some limitations. First of all, we did not
evaluate our children for lactase deficiency or lactose
intolerance. Lactase deficiency is common in adults with
chronic IBD (29). Complete avoidance of milk and milk
products can obviate the symptoms of lactose malabsorp-
tion, although decreasing the milk intake may also prevent
discomfort. As many as 80% of gastroenterologists surveyed
indicated that they have recommended avoidance of milk
and milk products to patients with UC (29). It has been
reported that more than one-third of paediatric patients
with IBD have lactase deficiency. Nevertheless, avoidance
of a lactose-containing diet should not be routinely recom-
mended to paediatric patients with IBD until evaluation for
lactase deficiency or lactose intolerance is performed (30).
Another limitation of our study is the small number of
patients. Because we had negative results (i.e., we did not
find a statistical difference), and the sample size of the
cohorts is somewhat small, it is likely that the lack of
significant difference occurred by chance. However,
because there are no trends towards significance, we doubt
that there is the risk of a type II statistical error in our study.
Therefore, we believe that CMP elimination diet does not
appear to be useful in the therapy of UC of children.
In conclusion, data of this paediatric, randomized trial
suggest that CMP elimination has no role in the manage-
ment of UC in non-sensitized children. Further larger
studies are needed to evaluate the efficacy of the CMP
exclusion diet on the induction and maintenance of remis-
sion in UC atopic children.
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